News | Remote Monitoring | June 13, 2023

REACT DX Registry Highlights Relevance of Atrial High-Rate Episode Remote Monitoring in ICD Patients

In combination with BIOTRONIK Home Monitoring the DX ICD system is an effective and convenient way to detect AHRE and monitor atrial fibrillation events and burden 

In combination with BIOTRONIK Home Monitoring the DX ICD system is an effective and convenient way to detect AHRE and monitor atrial fibrillation events and burden

June 13, 2023 — A recent study highlights that implantable cardioverter-defibrillator (ICD) patients with new-onset atrial high-rate episodes (AHRE) often show high stroke risk while not being on oral anticoagulation (OAC), underlining the relevance of continuous AHRE burden monitoring.1 The study also reports that the combination of BIOTRONIK’s unique DX ICD system with Home Monitoring is an effective and convenient way to detect AHRE.1 

REACT DX is a prospective, multi-center registry that enrolled 234 de novo ICD patients from 14 centers in Germany. It assessed the incidence of new-onset AHRE in an ICD population and the physicians’ reaction using the DX ICD system, a single-chamber ICD enhanced with a floating atrial sensing dipole. Performed in a real-life setting, REACT DX demonstrated the in-practice utility of DX Technology in combination with Home Monitoring for remote AHRE detection, atrial fibrillation (AF) diagnosis and subsequent therapy decision making. 

"AHRE can be a precursor or subclinical form of AF, which can increase the risk of stroke and other cardiovascular complications. Its timely detection and burden assessment is therefore crucial for a timely response, for example in the form of stroke prevention," says PD Dr. Carsten Lennerz, Senior Physician, German Heart Centre Munich, Department of Electrophysiology, Technical University of Munich, Germany. "As demonstrated by the study, the detection of new-onset AHRE by the DX ICD system in combination with Home Monitoring often led to initiation of oral anticoagulation for stroke prevention." 

However, the study findings suggest that the time period until therapy initiation could be reduced further. To support this and harness the full potential of DX and Home Monitoring, the study authors propose a specific protocol for managing remotely detected AHRE. This protocol, a simple decision tree, is based on each patient’s AHRE burden and stroke risk and aims to improve response times for OAC prescription.  

"The results of the REACT DX registry further strengthen the already substantial body of clinical evidence supporting the value of DX Technology in combination with Home Monitoring. Moreover, they emphasize the potential benefits for patients and clinicians, paving the way for more prompt, precise and patient-specific care. We are committed to providing innovative healthcare solutions that deliver real-world results and empower clinicians with tools which can ultimately improve patient outcomes," said Dr. Andreas Hecker, President CRM/EP at BIOTRONIK

The REACT DX study adds to the body of research supporting the benefits of DX Technology, extending the clinical evidence. Notably, the MATRIX study, the largest clinical evaluation of DX Technology to date2, has also recently been published. 

For more information: https://www.biotronik.com/en-de 

 

References: 

  1. O'Connor, Matthew et al. (2022): REACT DX registry: Real world REACTion to atrial high rate episodes detected in implantable cardioverter-defibrillator recipients with a DX lead. In Technol Health Care. 2022 Nov 17. doi: 10.3233/THC-220432. Online ahead of print. 
  2. Hindricks G., Theuns, D., Bar-Lev D. et al.: Ability to remotely monitor atrial high-rate episodes using a single-chamber implantable cardioverter-defibrillator with a floating atrial sensing dipole, EP Europace, 2023;, euad061, https://doi.org/10.1093/europace/euad061 

Related Content

Feature | Remote Monitoring | By Arnaud Rosier, MD, PhD

This past spring, electrophysiology experts issued new recommendations for remote monitoring of cardiovascular ...

Home November 20, 2023
Home
News | Remote Monitoring

November 9, 2023 — According to a recent survey of healthcare providers (HCPs), 93 percent of clinicians are currently ...

Home November 09, 2023
Home
News | Remote Monitoring

July 21, 2023 — AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today ...

Home July 21, 2023
Home
News | Remote Monitoring

July 11, 2023 — FIRE1 announced that the first U.S. patients have been successfully implanted with its FIRE1 System for ...

Home July 11, 2023
Home
News | Remote Monitoring

June 21, 2023 — Qardio, a leading innovator in healthcare technology, has unveiled its groundbreaking Livestream ...

Home June 21, 2023
Home
News | Remote Monitoring

May 8, 2023 — Ucardia, a cardiac conditioning software developer, announced today that it has reached an agreement to ...

Home May 08, 2023
Home
News | Remote Monitoring

March 28, 2023 — Royal Philips has announced its debut of Philips Virtual Care Management, a comprehensive approach to ...

Home March 28, 2023
Home
News | Remote Monitoring

December 15, 2022 — physIQ announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable ...

Home December 15, 2022
Home
News | Remote Monitoring

December 8, 2022 — Heart disease is the number one killer in the U.S., and high-fidelity monitoring is the beginning of ...

Home December 08, 2022
Home
News | Remote Monitoring

September 8, 2022 — PrepMD RMS, the premier cardiac clinical solutions company, announced today the acquisition of the ...

Home September 08, 2022
Home
Subscribe Now